FIELD: medicine.
SUBSTANCE: present invention refers to neurology and psychiatry, and concerns treating Alzheimer's disease. That is ensured by administering a pharmaceutical composition containing an active agent which causes a lower level of systemic immunosuppression. Agents used are antibodies neutralizing PD-1, PD-L1, or TIM-3. Introduction is ensured by at least two therapeutic courses. Each therapeutic course includes a series of sessions, comprising administering a pharmaceutical composition to a patient, followed by an interval in the treatment without administering the pharmaceutical composition to the patient, and wherein intervals without introduction are longer than periods of honey with repeated introduction sessions during therapeutic course.
EFFECT: such mode of introduction provides transient reduction of level of systemic immunosuppression, which, in its turn, promotes improvement of cognitive status of patients with Alzheimer's disease.
14 cl, 16 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| REDUCED SYSTEMIC LEVELS OR ACTIVITY OF REGULATORY T-CELLS FOR TREATING DISEASE AND CENTRAL NERVOUS SYSTEM INVOLVEMENT | 2017 |
|
RU2815892C1 |
| REDUCED SYSTEMIC LEVEL OF REGULATORY T-CELLS OR THEIR ACTIVITY FOR TREATING CNS DISEASES AND TRAUMAS | 2016 |
|
RU2741366C2 |
| COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DISTURBANCES | 2005 |
|
RU2387453C2 |
| CARBOHYDRATE-MODIFIED PARTICLES AND POWDERED COMPOSITIONS FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2752620C2 |
| PEPTIDE TOLEROGENIC COMPOUND | 2021 |
|
RU2766340C1 |
| METHODS AND COMPOSITIONS FOR TREATING LUPUS | 2010 |
|
RU2607022C2 |
| METHOD FOR PRODUCING AN ANTI-INFLAMMATORY AGENT BASED ON MAMMALIAN SPLEEN PEPTIDES, AGENT PRODUCED THEREBY AND APPLICATION THEREOF | 2021 |
|
RU2790158C1 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| ALPHA-SYNUCLEIN MODULATORS | 2018 |
|
RU2797677C2 |
